

Case Study

Phase 3 CAR T vs SOC in Relapse Refractory Multiple Myeloma (RRMM)

Assay Validation, Expertise And Continued Partnership With A Major Pharma

Scope

Patients Enrolled: 524

Sites: 95

Countries: 17

Regions: EU, US, Asia

Study duration: 32 months

Cerba Research validated a CAR T exploratory panel and a PK panel (primary endpoint)

Key Achievements

- ↑ Assay Validation fine-tuned with patient samples & spiked samples
- ↑ Strong established relationship with major pharma sponsor
- ↑ Involved in CAR T program early on
- ↑ ~7700 samples managed to date

Timeline



Challenges

Cerba Research involved in ~10 specialty tests

Such as immunophenotyping for a CAR T exploratory panel & FCM

Tracking PK as a primary endpoint

Solutions

Subcontracted some specialty tests

In house FCM design & validation

Cerba Research Data In-house (MSN F82); SOC=Standard Of Care; RRMM=Relapsed or Refractory Multiple Myeloma; FCM=Flow CytoMetry; FPFV=First-Patient First-Visit; LPLV=Last-Patient Last-Visit; DBL=DataBase Lock CAR T= Chimeric Antigen Receptor T cells